Head-to-head evidence
Ainuovirine vs Elsulfavirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Ainuovirine
Marketed by Kainos Medicine and partners
NCT01348516 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: June 2028 · NCT07631897 (registry estimate)
Elsulfavirine · Elpida
Marketed by Viriom
NCT02489461 · Phase 2/3 · completed
The study randomized 150 participants and used double blinding with an active efavirenz comparator. Its primary endpoint was the proportion with HIV-1 RNA below 400 copies/mL at Week 12, but no results are posted, so the outcome comparison cannot be assessed.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ainuovirine's landscape · Elsulfavirine's landscape